Rabbit Anti-Human FOXA2 monoclonal antibody, clone KN21-75

Long non-coding RNA-neighboring enhancer of FOXA2 (lncRNA-NEF) is a recently identified tumor suppressor in hepatocellular carcinoma. The present study aimed to investigate the role of lncRNA-NEF in small cell lung carcinoma (SCLC). Expression levels of lncRNA-NEF in the lung biopsy tissues and plasma samples from patients with SCLC and from healthy controls were detected using reverse transcription-quantitative polymerase chain reaction. Receiver operating characteristic curve analysis was performed to evaluate the diagnostic value of lncRNA-NEF as a marker of SCLC. The association between plasma levels of lncRNA-NEF and the clinical data of patients was analyzed using the (2) test. An lncRNA-NEF expression vector was prepared and transfected into SCLC cells, and cellular migration and invasion were detected using Transwell migration and invasion assays, respectively. The expression of transforming growth factor 1 (TGF-1) was detected using western blotting. The results demonstrated that the expression level of lncRNA-NEF was lower in patients with SCLC compared with that in healthy controls. The expression level of lncRNA-NEF in the plasma was associated with distant tumor metastasis. lncRNA-NEF overexpression inhibited SCLC cell migration and invasion, resulting in TGF-1 downregulation, while treatment with exogenous TGF-1 reduced the inhibitory effects of lncRNA-NEF overexpression on migration and invasion. Therefore, it was concluded that lncRNA-NEF inhibited the migration and invasion of SCLC cells, which was potentially associated with the downregulation of TGF-1.

In recent years, stem cells have gained much attention for the treatment of neurodegenerative diseases. However, inducing neural stem cell directionally differentiation is a difficult problem in the treatment of Parkinson's disease (PD) by stem cell therapy. Plastrum Testudinis (PT) can enhance the number of TH-positive neurons in the PD rat brain substantia nigra, but the underlying mechanism has not been clarified. Here, we aimed at further investigating the mechanism by which PT can promote NSC differentiation into dopaminergic neurons. A rat model of PD was used for detecting the effect of PT on the rat brain substantia nigra in vivo. The results showed the expressions of tyrosine hydroxylase (TH) and TET1 enzyme were increased after treatment with PT. Consequently, Plastrum Testudinis extracts (PTEs) were used for inducing NSC differentiation into dopaminergic neurons ex vivo. During differentiation of NSCs induced by PTE, TH expression was increased, with a concomitant increase in both TET1 and FoxA2. Next, we performed coimmunoprecipitation analysis to examine the interaction between TET1 protein and FoxA2 protein. Our results show that PTE can increase the binding rate of TET1 and FoxA2. Thus, our findings show that PTE can increase the efficiency of NSCs to directionally differentiate into dopaminergic neurons and provide experimental evidence for PT in the treatment of Parkinson's disease.